Pan-cancer landscape of CD274 (PD-L1) copy number changes in 244 584 patient samples and the correlation with PD-L1 protein expression

INTRODUCTION: Several studies have shown clinical outcomes data that support the use of CD274 (PD-L1) copy-number (CN) gains and/or losses as a biomarker for immune checkpoint inhibitor (ICPI). Here, we present the landscape of CD274 CN changes across a large cohort of solid tumor cases and correlat...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Richard S.P., Murugesan, Karthikeyan, Montesion, Meagan, Pavlick, Dean C., Mata, Douglas A., Hiemenz, Matthew C., Decker, Brennan, Frampton, Garrett, Albacker, Lee A., Ross, Jeffrey S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Immunotherapy Biomarkers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8112409/
https://www.ncbi.nlm.nih.gov/pubmed/33972391
http://dx.doi.org/10.1136/jitc-2021-002680

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8112409/
https://www.ncbi.nlm.nih.gov/pubmed/33972391
http://dx.doi.org/10.1136/jitc-2021-002680

Ejemplares similares